Dapagliflozin and spironolactone for severe aortic stenosis before valve replacement
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests two medicines (dapagliflozin and spironolactone) to see if they help the heart muscle recover and improve symptoms after aortic valve replacement. It's for people with severe narrowing of the main heart valve who are scheduled for valve surgery or a less invasive procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have severe narrowing of your aortic valve (the main valve that sends blood to your body) and are scheduled for valve replacement.
- Your heart's pumping strength is at least 40% (measured as ejection fraction).
- You are not currently taking or allergic to the trial medicines.
- You do not have advanced kidney disease, high potassium, or a serious liver condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether replacing a narrowed heart valve early helps people who have severe aortic stenosis but no symptoms. You would be randomly assigned to early valve replacement or careful waiting with regular check-ups.
This trial studies a new device that can replace a tight aortic heart valve through a catheter (not open-heart surgery). It focuses on people with severe, symptomatic valve narrowing who are higher risk for surgery and checks how safe the procedure is and how well it works.
This study tests whether angiotensin receptor blocker (ARB) blood pressure medication helps people with mild to moderate aortic stenosis (a narrowing of the heart’s main valve). It looks at safety and whether the treatment offers benefit for your heart and blood flow.
This trial tests whether replacing a badly narrowed aortic valve earlier—even when you feel fine—can prevent future heart problems. It compares early valve replacement (through a catheter or surgery) versus standard watchful waiting.
This study compares doing aortic valve replacement sooner versus waiting, in people with moderate aortic valve narrowing plus at least moderate leakage in the mitral valve. It aims to see which timing improves heart symptoms and outcomes while keeping treatment safe.
This trial tests enavogliflozin (a diabetes medication that may help the heart) in people who have had a TAVR procedure for severe aortic stenosis. It looks at whether the medicine can improve outcomes for people with symptoms and mildly reduced or preserved pumping function.
Hear when a new Aortic Stenosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.